# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Craig-Hallum maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $24 to $26.
B. Riley Securities analyst Sahil Kazmi reiterates Harrow (NASDAQ:HROW) with a Buy and raises the price target from $26 to $29.
Harrow Health (NASDAQ:HROW) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.2...